drugset / Trial / NCT00060268

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

NCT00060268 ↗

Phase 1/2 Completed 11 enrolled Roswell Park Cancer Institute
NaSingle-groupTreatment

Summary

RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have obstructive esophageal tumors.

Timeline

Start
1997-01
Primary completion
2003-09
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a Unknown — Intravenous

Indications